[1] Henri Mondor Hosp, AP HP, Dermatol Dept, Creteil, France
[2] French Investigators Skin Adverse React Drugs FISA, Paris, France
[3] Refence Ctr Tox Bullous Dis & Severe Drug React TO, Creteil, France
[4] Univ Paris Est Creteil EpiDermE, Creteil, France
[5] CHRU Tours, NSERM, CIC1415, Tours, France
[6] CHU Bordeaux, Dermatol Dept, Bordeaux, France
[7] CHU Edouard Herriot, Dermatol Dept, Lyon, France
[8] CHU Dijon, Dermatol Dept, Dijon, France
[9] Sorbonne Univ, Hop Tenon, AP HP, INSERM,Inst Pierre Louis Epidemiol & Sante Publ,De, Paris, France
[10] CHU Nice, Dermatol Dept, Nice, France
[11] CHU Charles Nicolle, Dermatol Dept, Rouen, France
[12] CHU Tours, Dermatol Dept, Tours, France
[13] Hop Xavier Bichat, AP HP, Dermatol Dept, Paris, France
[14] Timone Hosp, AP HP, Dermatol Dept, Marseille, France
[15] CHU Clermont Ferrand, Hop Estaing, Dermatol Dept, Clermont Ferrand, France
[16] CHU Caen, Dermatol Dept, Caen, France
[17] CHU Amiens, Dermatol Dept, Amiens, France
[18] Henri Mondor Hosp, AP HP, Unite Rech Clin, Creteil, France
[19] Univ Nantes, Univ Tours, INSERM, SPHERE U1246, Tours, France
[20] Hop Univ Pitie Salpetriere, AP HP, Facial Dermatosis Clin, ENT Dept, Paris, France